Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Clinical Trial
    Online

    Communication Bridge 3 (CB3) Clinical Trial

    What is this Study about?

    The Communication Bridge 3 Study is focused on helping adults with mild to moderate Primary Progressive Aphasia (PPA), a condition that affects language abilities due to neurodegenerative diseases. The study aims to improve functional communication and life participation by providing structured language and communication support remotely through video conferencing.

    Participants work with speech-language pathologists to practice communication techniques and learn strategies to address daily communication challenges. The study involves a series of therapy sessions, assessments, and follow-up evaluations to measure changes in communication and participation over time. By tracking participants' progress, the study hopes to identify effective approaches for enhancing quality of life for those living with PPA and their care partners.

    Eligibility Criteria

    You are eligible to participate if you speak English as a primary language, a confirmed diagnosis of PPA in mild to moderate impairment stage, a communication partner that is willing to participate, and sufficient internet connection.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1)

    What is this Study about?

    The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.

    Eligibility Criteria

    Male or female participants aged 50 to 80 years of age
    MCI or Mild AD at Screening
    Must have a study partner

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease (ALTITUDE-AD)

    What is this Study about?

    The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.

    Eligibility Criteria

    Male or female participants aged 50 to 90 years of age
    MCI due AD or probable AD.
    Must have a study partner

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzheimer's Disease (Polaris-AD)

    What is this Study about?

    This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.

    Eligibility Criteria

    Male or female participants aged 55 to 90 years of age
    MCI or Mild AD at Screening
    Must have a study partner

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    The impact of melatonin on sleep and sleep dependent memory consolidation

    What is this Study about?

    The uOttawa Sleep Laboratory is looking for adults to participate in a research study investigating the relationship between sleep and memory. Brain activity will be recorded using functional electroencephalography (EEG).

    Eligibility Criteria

    To be included participants must be:

    - Right-handed

    - Native English speakers

    - No psychiatric disorders (past or present)

    - Healthy adults, or those with memory complaints, or those with mild cognitive impairment

    Recruitment End Date

    Find Out More
  • Clinical Trial
    Ontario

    Accelerated intermittent theta burst stimulation to enhance cognitive function and balance in dementia

    What is this Study about?

    McMaster University, in partnership with Ressam Gardens Memory Care Community, is conducting a study on the effects of brain stimulation in individuals aged 50 and older with dementia or memory loss. The research focuses on using repetitive transcranial magnetic stimulation (rTMS), a non-invasive technique that delivers magnetic pulses to the brain, to enhance cognitive function and balance. The goal is to extend the positive effects of brain stimulation in improving cognition and balance in individuals with dementia.

    Eligibility Criteria

    You are eligible to participate if you…

    1.) Diagnosed with Dementia and/or memory loss by a clinician

    2.) Exhibit adequate oral communication skills and cognitive function sufficient to obtain a score ranging between 10-27 on the Mini-Mental State Exam

    3.) Walk or stand with or without personnel or assistive devices

    4.) Individuals must be greater than or equal to 50 years of age

    Recruitment End Date

    Find Out More
  • Clinical Trial
    Online & In-Person

    Helping persons with dementia sleep better: a pilot program for care partners

    What is this Study about?

    The aim of this study is to assess the feasibility of the Nighttime Insomnia Treatment and Education for Canadians with Alzheimer’s Disease (NITE-CAD) program. NITE-CAD is a 6-week lifestyle intervention program aimed to improve sleep in people living with dementia by supporting their care partners. The information gathered will be used to improve the program for future offerings.

    Eligibility Criteria

    • Care partner to someone living with dementia with sleep difficulties

    • Are living with dementia experiencing sleep difficulties, with a live-in care partner who is interested in participating

    • Able to speak and understand English

    • Have access to the internet and a computer with a camera and microphone

    • Able to participate in an exercise program

    • Sufficient cognitive function to follow two-step commands.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    Online

    Alleviating dementia caregiver stress: Implementation and evaluation of a novel mobile application

    What is this Study about?

    Caregivers of people living with dementia experience significant stress which can negatively affect their mental health. The overall aim of the current study is to evaluate a newly developed app that focuses on providing stress-management strategies for family caregivers of people living with dementia. Findings from the study of an app that aims to address the stressors associated with caregiving has the potential to improve the quality of life of caregivers of people living with dementia.

    Eligibility Criteria

    - Providing informal and unpaid care (e.g., spouses, children) for people living with dementia

    - Providing primary care (i.e., most of the care or equally shares the care with another individual such as a mother or sibling) for the person living with dementia

    - Own a smartphone (e.g., iPhone, Android)

    - Not currently using a mobile app created for caregivers

    - Ability to speak English

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's (IGC-AD1-P2)

    What is this Study about?

    The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.

    Eligibility Criteria

    60+
    Diagnosis of Alzheimer's disease
    Must have a study partner

    Recruitment End Date

    Find Out More